Brands & Strategies: Psoriasis

Table of Contents

Table of Exhibits

• Market Summary
• Competitive Landscape
• Brand Overview
• Physician Perspectives

• Scope of Report
• Primary Research Methodology

• Psoriasis Background
• Prevalence and Diagnosis
  • Major Markets Statistics and Key Findings
  • US Statistics and Key Findings
  • Europe Statistics and Key Findings
  • Japan Statistics and Key Findings
• Prescribers
  • General Prescriber Trends
  • Key Drivers of Prescriber Decisions
• Reimbursement Issues
• Treatment Dynamics
  • Existing Therapies
  • Emerging Therapies

• Overview of Competitive Landscape
• Promotional Spending
• Survey Results: Physician Perceptions
  • Perceptions of Competitors in the Psoriasis Market
  • Perceptions of Brands in the Psoriasis Market

• Enbrel
  • Development and Commercial Overview
  • Current Positioning
  • Enbrel Competitive Analysis
  • Key Brand Strategies
    • Current Strategy in the Psoriasis Market
    • Lifecycle management and future strategy
  • Future Positioning
  • Amgen
    • Inflammatory Disease Product Portfolio
    • Goals and Vision in Inflammatory Disease
    • Current Positioning
    • Market Strategy
    • Outlook
  • Wyeth
    • Inflammatory Disease Product Portfolio
    • Goals and Vision in Inflammatory Disease
    • Current Positioning
    • Market Strategy
    • Outlook
• Raptiva
  • Development and Commercial Overview
  • Current Positioning
  • Raptiva Competitive Analysis
  • Key Brand Strategies
    • Current Strategy in the Psoriasis Market
    • Lifecycle Management and Future Strategy
  • Future Positioning
  • Genentech
    • Immunology Product Portfolio
    • Goals and Vision in Immunology
    • Current Positioning
    • Market Strategy
    • Outlook
  • Merck Serono
    • Autoimmune & Inflammatory Product Portfolio
    • Goals and Vision in Autoimmune & Inflammatory Disease
    • Current Positioning
    • Market Strategy
    • Outlook
• Remicade
  • Development and Commercial Overview
  • Current Positioning
  • Remicade Competitive Analysis
  • Key Brand Strategies
    • Current Strategy in the Psoriasis Market
    • Lifecycle Management and Future Strategy
  • Future Positioning
  • Centocor
    • Immune-Mediated Inflammatory Disorder Product Pipeline
    • Goals and Vision in Inflammatory Disease
    • Current Positioning
    • Market Strategy
    • Outlook
  • Schering-Plough
    • Inflammation Product Portfolio
    • Goals and Vision in Inflammatory Disease
    • Current Positioning
    • Market Strategy
    • Outlook
• Humira
  • Development and Commercial Overview
  • Current Positioning
  • Humira Competitive Analysis
  • Key Brand Strategies
    • Current Strategy in the Psoriasis Market
    • Lifecycle Management and Future Strategy
  • Future Positioning
  • Abbott Laboratories
    • Immunology Product Portfolio
    • Goals and Vision in Immunology
    • Current Positioning
    • Market Strategy
    • Outlook
• Amevive
  • Development and Commercial Overview
  • Current Positioning
  • Amevive Competitive Analysis
  • Key Brand Strategies
    • Biogen/Biogen Idec' s Strategies for Amevive
    • Astellas Pharma' s Strategies for Amevive
  • Future Positioning
  • Astellas Pharma
    • Dermatology Product Portfolio
    • Current Positioning and Market Strategy
    • Outlook

• CNTO-1275
  • Overview
  • CNTO-1275 Competitive Analysis
  • Key Brand Strategies
  • Future Positioning
• Voclosporine (ISA-247)
  • Overview
  • Voclosporine Competitive Analysis
  • Key Brand Strategies
  • Isotechnika

• Drug Sales by Region
• Drug Sales by Class

Acronyms and Abbreviations

Bibliography

Methodology

• Epidemiological Forecast Methodology
• Market Forecast Methodology
• Competitive Analysis Methodology

• Exhibit ES-1: Key Parameters of the Psoriasis Market
• Exhibit ES-2: Psoriasis Branded Market, ($US), Major Markets, 2005- 2010
• Exhibit ES-3: Psoriasis Market Competitive Position, 2005 and 2010
• Exhibit ES-4: Psoriasis Brand Sales ($US), by Brand, as a Percent of Total, 2005 and 2010
• Exhibit ES-5: Dermatologist Rankings of Companies in Psoriasis Treatment
• Exhibit ES-6: Humira in Dermatologist' s Line of Therapy

• Exhibit 1-1: Surveyed Physicians' Years of Practice
• Exhibit 1-2: Surveyed Physicians' Patients per Month
• Exhibit 1-3: Surveyed Physicians' Geographic Distribution

• Exhibit 2-1: Drug Classes Used in the Treatment of Psoriasis
• Exhibit 2-2: Prevalent and Diagnosed Psoriasis Cases, Major Markets
• Exhibit 2-3: Prevalent and Diagnosed Psoriasis Cases, US
• Exhibit 2-4: Prevalent and Diagnosed Psoriasis Cases, Europe
• Exhibit 2-5: Prevalent and Diagnosed Psoriasis Cases, Europe, Continued
• Exhibit 2-6: Prevalent and Diagnosed Psoriasis Cases, Japan
• Exhibit 2-7: Dermatologist Information Channels Used in Psoriasis Treatment
• Exhibit 2-8: End Points Used in Clinical Trials for Psoriasis, 2007
• Exhibit 2-9: Biologic Agents in the Psoriasis Market, 2006
• Exhibit 2-10: Approved Indications for Biologic Therapies in Current Psoriasis Treatment
• Exhibit 2-11: Timeline of Recent Approvals in the Psoriasis Market, 1998- 2007

• Exhibit 3-1: Psoriasis Market Competitive Position, 2005 and 2010
• Exhibit 3-2: Market for Biologic Psoriasis Therapies, by Company, 2005-2010
• Exhibit 3-3: Psoriasis Market Share, by Competitor, as a % of Total, 2005
• Exhibit 3-4: Psoriasis Market Share, by Competitor, as a % of Total, 2010
• Exhibit 3-5: Promotional Spending, by Brand, as a % of Total Spending for All Indications of Biologic Agents in Psoriasis, 2004- 2006
• Exhibit 3-6: Promotional Spending, by Competitor, as a % of Total Spending for All
• Indications of Biologic Agents in Psoriasis, 2004- 2006 [Tabular Format]
• Exhibit 3-7: Promotional Spending, by Competitor, as a % of Total Spending for All
• Indications of Biologic Agents in Psoriasis, 2004- 2006 [Graphical Format]
• Exhibit 3-8: Dermatologist Perceptions of Psoriasis Market Competitors, 2007
• Exhibit 3-9: Dermatologist Rankings of Best Company in the Psoriasis Market, 2007
• Exhibit 3-10: Dermatologist Efficacy Rankings, by Brand, 2007
• Exhibit 3-11: Dermatologist Safety Rankings, by Brand, 2007
• Exhibit 3-12: Dermatologist Convenience Rankings, by Brand, 2007
• Exhibit 3-13: Dermatologist Reimbursement Rankings, by Brand, 2007
• Exhibit 3-14: Dermatologist-Reported Rankings of Biologic Therapies in Psoriasis, 2005 versus 2007
• Exhibit 3-15: Dermatologist Efficacy Rankings, Detail, 2007
• Exhibit 3-16: Dermatologist Safety Rankings, Detail, 2007
• Exhibit 3-17: Dermatologist Safety Rankings, Detail (continued), 2007
• Exhibit 3-18: Dermatologist Convenience Rankings, Detail, 2007

• Exhibit 4-1: Established Brands in the Psoriasis Market, 2006 and 2010
• Exhibit 4-2: Timeline of Notable Milestones in Enbrel' s Development for Psoriasis
• Exhibit 4-3: Enbrel' s Rank Among Biologic Therapies in Psoriasis Treatment
• Exhibit 4-4: Predominant Reasons for Discontinuing Enbrel Therapy, Cumulative Rankings, 2007
• Exhibit 4-5: Enbrel' s Rank among Biologic Therapies for Psoriasis, by Key Efficacy and Safety Attributes
• Exhibit 4-6: Enbrel' s Rank among Biologic Therapies for Psoriasis, by Key Convenience Attributes
• Exhibit 4-7: Enbrel' s Rank among Biologic Therapies for Psoriasis, by Long-term Safety Data
• Exhibit 4-8: Dermatologist Rankings of TNF-ƒ¿ Inhibitor Efficacy in Psoriasis
• Exhibit 4-9: Summary of Key Clinical Trials Supporting Enbrel' s Psoriasis Approvals
• Exhibit 4-10: Select Ongoing Phase III Clinical Trials for Enbrel in Psoriasis
• Exhibit 4-11: Select Ongoing Phase IV Clinical Trials for Enbrel in Psoriasis
• Exhibit 4-12: Enbrel Psoriasis Revenue ($US), by Country, 2005- 2010
• Exhibit 4-13: Enbrel Psoriasis Revenue ($US), by Country, 2005- 2010
• Exhibit 4-14: Price to Treat per Day ($US), Enbrel, by Country, 2006
• Exhibit 4-15: Amgen' s Pharmaceutical Product Revenue, by Brand, 2006
• Exhibit 4-16: Summary of Amgen' s Inflammatory Disease Product Portfolio
• Exhibit 4-17: Physician-Reported Rankings of Amgen/Wyeth
• Exhibit 4-18: Enbrel Revenue ($US), by Company and Region, 2005- 2010 [Graphical Format]
• Exhibit 4-19: Enbrel Revenue ($US), by Company and Region, 2005- 2010 [Tabular Format]
• Exhibit 4-20: Wyeth' s Pharmaceutical Product Revenue, with Enbrel Revenue Allocation, 2006
• Exhibit 4-21: Summary of Wyeth' s Inflammatory Disease Product Portfolio
• Exhibit 4-22: Wyeth' s Enbrel Psoriasis Revenue ($US), by Country, 2005- 2010, [Graphical Format]
• Exhibit 4-23: Wyeth' s Enbrel Psoriasis Revenue ($US), by Country, 2005- 2010, [Tabular Format]
• Exhibit 4-24: Important Milestones in Raptiva' s Development for Psoriasis
• Exhibit 4-25: Raptiva' s Rank Among Biologic Therapies in Psoriasis Treatment
• Exhibit 4-26: Raptiva' s Rank Among Biologic Agents, by Efficacy and Safety Attributes
• Exhibit 4-27: Raptiva' s Rank Among Biologic Agents in terms of Continuous Monitoring Requirements
• Exhibit 4-28: Predominant Reasons for Discontinuing Raptiva Therapy
• Exhibit 4-29: Clinical trials cited by the FDA in Raptiva' s approval using predominantly XOMA-produced drugs
• Exhibit 4-30: Clinical Trials Cited by the FDA in Raptiva' s Approval Using Genentech- Produced Raptiva
• Exhibit 4-31: Raptiva Psoriasis Revenue ($US), by Country, 2005- 2010
• Exhibit 4-32: Raptiva Psoriasis Revenue ($US), by Country, 2005- 2010
• Exhibit 4-33: Price to Treat per Day ($US), Raptiva, by Country, 2006
• Exhibit 4-34: Genentech Product Revenue and Growth, 2006
• Exhibit 4-35: Summary of Genentech' s Immunology Product Portfolio
• Exhibit 4-36: Merck Serono' s Products and Revenue
• Exhibit 4-37: Summary of Merck Serono' s Autoimmune & Inflammatory Product Portfolio
• Exhibit 4-38: Timeline of Notable Milestones in Remicade' s Development for Psoriasis
• Exhibit 4-39: Remicade' s Revenue Rank in Marketed Biologic Agents, by Indication
• Exhibit 4-40: Remicade' s Rank Among Biologic Therapies in Psoriasis Treatment, 2007
• Exhibit 4-41: Remicade' s Rank Among Biologic Therapies in Psoriasis Treatment, by Efficacy and Safety Attributes, 2007
• Exhibit 4-42: Remicade' s Rank Among Biologic Therapies in Psoriasis Treatment, by Efficacy and Safety Attributes, 2007
• Exhibit 4-43: Remicade' s Safety Rank Among Biologic Agents
• Exhibit 4-44: Summary of Key Clinical Trials Supporting Remicade' s Psoriasis Approvals
• Exhibit 4-45: Select Ongoing or Unreported Phase III Clinical Trials for Remicade in Psoriasis
• Exhibit 4-46: Remicade Psoriasis Revenue ($US), by Country, 2005- 2010
• Exhibit 4-47: Remicade Psoriasis Revenue ($US), by Country, 2005- 2010
• Exhibit 4-48: Price to Treat per Day ($US), Remicade, by Country, 2006
• Exhibit 4-49: Summary of Centocor and J&J' s IMID Product Portfolio
• Exhibit 4-50: Centocor' s Psoriasis Revenue ($US), by Country and Brand, 2005- 2010
• Exhibit 4-51: Schering-Plough' s Pharmaceutical Revenue, 2006
• Exhibit 4-52: Summary of Schering-Plough' s Inflammation Product Portfolio
• Exhibit 4-53: Important Milestones in Humira' s Development for Psoriasis
• Exhibit 4-54: Humira' s Rank among Biologic Therapies for Psoriasis
• Exhibit 4-55: Humira' s Rank among Biologic Agents, by Dosing Attributes
• Exhibit 4-56: Humira versus Enbrel, Rank among Biologic Agents, by Long-Term Safety Data
• Exhibit 4-57: Humira' s Phase III Trials in Psoriasis
• Exhibit 4-58: Humira' s Current and Forecast Position in Dermatologist' s Line of Therapy for Moderate to severe Psoriasis
• Exhibit 4-59: Physician-Selected Patient Groups Appropriate for Humira Therapy following FDA Approval
• Exhibit 4-60: Humira vs. Enbrel, Rank among Biologic Agents, by Short-Term Efficacy
• Exhibit 4-61: Humira versus Enbrel, Rank among Biologic Agents, by Maintenance Efficacy
• Exhibit 4-62: Humira versus Enbrel, Rank among Biologic Agents, by Delivery Method
• Exhibit 4-63: Humira versus Enbrel, Rank among Biologic Agents, by Dosing Frequency
• Exhibit 4-64: Humira Psoriasis Revenue ($US), by Country, 2005- 2010
• Exhibit 4-65: Humira Psoriasis Revenue ($US), by Country, 2005- 2010
• Exhibit 4-66: Price to Treat per Day ($US), Humira, by Country, 2005
• Exhibit 4-67: Abbott' s Pharmaceutical Revenues, by Brand and Business Revenues, by Business Segment
• Exhibit 4-68: Summary of Abbott' s Immunology Product Portfolio
• Exhibit 4-69: Notable Milestones in Amevive' s Development for Psoriasis
• Exhibit 4-70: Amevive' s Rank among Biologic Therapies for Psoriasis, by General Attributes
• Exhibit 4-71: Amevive' s Rank among Biologic Therapies for Psoriasis, by Key Efficacy and Safety Attributes
• Exhibit 4-72: Amevive' s Rank among Biologic Therapies for Psoriasis, by Key Convenience and Reimbursement Attributes
• Exhibit 4-73: Amevive Psoriasis Revenue ($US), 2005- 2010
• Exhibit 4-74: Amevive Psoriasis Revenue ($US), 2005- 2010
• Exhibit 4-75: Astellas' North American Pharmaceutical Revenue as a % of Total Revenue
• Exhibit 4-76: Physician-Reported Rankings of Astellas Pharma

• Exhibit 5-1: CNTO-1275' s Efficacy Results in its Phase II Psoriasis Trial
• Exhibit 5-2: Ongoing Phase III Trials of CNTO-1275 in Psoriasis
• Exhibit 5-3: CNTO-1275' s Attributes Compared to Enbrel
• Exhibit 5-4: Price Per Treated Day of Branded Agents for Psoriasis in 2010
• Exhibit 5-5: Voclosporine' s Completed Phase II/III Clinical Trials in Psoriasis
• Exhibit 5-6: Isotechnika' s Strategic Alliances

• Exhibit 6-1: Psoriasis Branded Therapies Market ($US), Major Markets, 2005- 2010 (Tabular Format)
• Exhibit 6-2: Psoriasis Branded Therapies Market ($US), Major Markets, 2005- 2010 [Graphical Format]
• Exhibit 6-3: Psoriasis Branded Therapies Market ($US), by Country, 2005- 2010 [Graphical Format]
• Exhibit 6-4: Psoriasis Branded Therapies Market ($US), by Country, 2005- 2010 [Tabular Format]
• Exhibit 6-5: Psoriasis Branded Therapies Market ($US), by Drug Class, 2005- 2010